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Abstract The neurobiological mechanisms of nocebos are
still poorly understood. Thirty-eight women participated in a
‘smell study’ using functional magnetic resonance imaging.
They were presented with an odorless stimulus (distilled wa-
ter) together with the verbal suggestion that this fluid has an
aversive odor which enhances disgust feelings. The nocebo
was presented while the participants viewed disgusting, fear-
inducing, and neutral images. Participants’ affective and neu-
ronal responses during nocebo administration were compared
with those in a control condition without nocebo. Twenty-nine
women (76%) reported perceiving a slightly unpleasant and
arousing odor. These ‘nocebo responders’ experienced in-
creased disgust during the presentation of disgusting images
in combination with the nocebo and showed enhanced left
orbitofrontal cortex (OFC) activation. It has been suggested
that the OFC is involved in the generation of placebo/nocebo-
related expectations and appraisals. This region showed in-
creased functional connectivity with areas involved in
interoception (insula), autobiographical memories (hippocam-
pus), and odor imagery (piriform cortex) during nocebo ad-
ministration. The nocebo-induced change in brain activation
was restricted to the disgust condition. Implications for psy-
chotherapy are discussed.
Keywords Nocebo . Disgust . Olfactory system . Functional
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Introduction
The neurobiological mechanisms underlying placebo effects,
particularly those relating to placebo analgesia, have been
extensively studied (for a review see Wager and Atlas 2015).
It has been shown that the administration of a physically and
pharmacologically inert drug, device or other type of interven-
tion reduces the level of pain experienced by patients, if they
believe they are receiving an active treatment. This positive
expectation, which can be elicited by means of learning expe-
riences, verbal suggestions or other contextual cues, is accom-
panied by specific changes in brain activation. Very consis-
tently these changes included increased activation of the
ventromedial/dorsolateral prefrontal cortex, and the
orbitofrontal cortex (OFC). The localized prefrontal activity
is thought to be involved in the generation of placebo-related
positive expectations and appraisals (Wager and Atlas 2015).
Flaten et al. (2011) have argued that such expectations lead to
pain relief via a decrease in negative emotions. Reduced acti-
vation during placebo analgesia can be found in those brain
regions involved in interoceptive awareness and pain process-
ing (e.g., insula, anterior cingulate cortex, periaqueductal
gray).
The opposite phenomenon, nocebo hyperalgesia, has
attracted less research attention. In general, nocebo effects
include the occurrence of negative symptoms, the worsening
of a condition, and the prevention of improvement after the
administration of an inert substance or a sham treatment.
Nocebo effects are a consequence of negative expectations
by the patients (for a review see Häuser et al. 2012). The
neuronal systems, which are activated by ‘nocebo expecta-
tions’ are still poorly understood, and it is a matter of debate
whether placebo and nocebo effects share a common brain
network or whether they are characterized by distinct
neuronal features. Schmid et al. (2013) demonstrated that
* Anne Schienle
anne.schienle@uni-graz.at
1 Clinical Psychology, University of Graz, BioTechMedGraz,
Universitätsplatz 2/DG, 8010 Graz, Austria
Brain Imaging and Behavior
DOI 10.1007/s11682-017-9675-1
deceptive information regarding an intravenous drug treat-
ment resulted in increased pain experience and insula activa-
tion during visceral stimulation (painful rectal distensions). In
a subsequent study by the authors (Schmid et al. 2015),
nocebo-responders (who had reported pain sensitization)
displayed increased activation in the insula, the somatosenso-
ry cortex and the amygdala during painful rectal stimulation.
In addition, the insula showed increased functional connectiv-
ity with the midcingulate cortex as a function of negative
expectations. Consequently, the insula was identified as a cen-
tral hub for the transmission of placebo as well as nocebo
effects.
Freeman et al. (2015) directly compared the effects of pla-
cebo and nocebo interventions. They administered a heat pain
stimulus together with an inert cream, which was explained as
being either a pain-reducing or pain-increasing substance. The
expectation of increased pain activated the insula, the OFC,
and the periaqueductal gray, whereas the placebo recruited the
striatum. These findings point to a completely separated
placebo/ nocebo network.
The majority of previous nocebo neuroimaging studies have
investigated nocebo effects in the context of pain (e.g., Kong
et al. 2008). Only rarely have other response systems been
analyzed via fMRI, e.g., nocebo effects on itch (Napadow
et al. 2015). The present nocebo study aimed at changing dis-
gust experiences and was based on previous observations of a
‘disgust placebo’ (Schienle et al. 2014a, b). The authors of that
study presented their disgust-prone participants with affective
images (disgusting, fear-eliciting, neutral) and administered a
placebo pill together with the verbal suggestion that this was an
effective ‘anti-nausea’ (disgust-reducing) medication. This in-
tervention very effectively diminished feelings of disgust: the
intensity of experienced revulsion was almost halved by the
placebo. This effect was accompanied by reduced insula acti-
vation. Psychophysiological interaction (PPI) analyses revealed
that placebo administration altered connectivity in a network
consisting of the insula, the amygdala, and the OFC.
Interestingly, the placebo did not evoke neuronal changes dur-
ing the presentation of fear-inducing pictures. These fear-
inducing pictures served as an ‘affective’ control condition in
the experiment. Thus, the placebo provoked emotion-specific
effects in accordance with the disgust-reducing suggestion.
A recent fMRI study (Schienle et al. 2017) directly com-
pared neuronal effects of explicit and implicit disgust regula-
tion (cognitive reappraisal vs. placebo administration) in
women with average disgust proneness. Relative to the pas-
sive viewing of disgust images, both reappraisal and placebo
treatment significantly reduced self-reported disgust. In addi-
tion, both regulation strategies were associated with similar
connectivity patterns. Placebo and reappraisal increased the
coupling between the OFC and the amygdala relative to pas-
sive viewing. The OFC is involved in cue–outcome learning
and reward/punishment expectations (Wager and Atlas 2015).
In contrast to these previous studies, the present experiment
focused on disgust-enhancing expectations. The participants
received the misinformation that an administered substance
(distilled water) would have a slightly aversive, disgusting
odor. Investigations with similar instructions have been con-
ducted previously. Jaén and Dalton (2014) exposed asthmatic
patients to a harmless odorant (rose scent). Half of the partic-
ipants were told that the odor might cause respiratory prob-
lems, whereas the other half received the information that the
odor was therapeutic. The patients in the nocebo condition
showed increased airway inflammation.
The design for the present nocebo study followed on from a
previous placebo experiment (Schienle et al. 2014a) regarding
the presentation of affective images from three categories (dis-
gust, fear, neutral). It was hypothesized that a ‘disgust nocebo’
would specifically increase experienced disgust during the
presentation of disgust images, while the other conditions
would not be affected. This should be accompanied by in-
creased brain activation as well as functional connectivity in
a network consisting of key regions involved in placebo/
nocebo effects (e.g., insula, OFC).
In an exploratory approach, it was investigated whether
nocebo responses in the context of disgust processing, would
be associated with trait disgust. This personality characteristic
refers to individual differences in sensitivity to disgust
(Schienle et al. 2002a). Disgust-prone subjects experience dis-
gust more frequently and more intensely across various situa-




Thirty-eight women were invited to a ‘smell study’. The cover
story stated that they would be presented with a disgusting
odor of very low intensity in order to test olfactory sensitivity.
All participants were recruited via announcements at the uni-
versity campus and had a high school diploma. The sample
had been restricted to women because there are significant sex
differences in disgust proneness (Schienle et al. 2002a).
Exclusion criteria consisted of mental disorders, medication,
and somatic problems as assessed by the Brief Symptom
Inventory (Derogatis 1993). Written informed consent was
obtained from all subjects. The study was conducted in accor-
dance with the Declaration of Helsinki and had been approved
by the ethics committee of the University of Graz.
From the 38 participants, nine were excluded from further
analysis because they did not respond to the nocebo sugges-
tion at all (‘non-responders’). Data from the remaining 29
right-handed, non-smoking, healthy women with a mean age
of 22.31 years (SD = 2.95) were analyzed.
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Materials
NoceboWe administered 0.2ml distilled water with green food
coloring to an odorless tape (labeled as ‘Olfatape’) attached
beneath the nose. The size of the tape was 4 cm × 1 cm (see
Fig. 1). During the application of Olfatape the experimenter
wore odorless gloves to prevent the participants from detecting
smells from the experimenter’s hand. The participants were
instructed that the fluid was a chemical (6-n-Propylthiouracil;
PROP) with an aversive odor (‘smells like sour milk, rancid
butter, vomit’). This fluid would be presented in a very low
dosage (just above the olfactory threshold). In addition, it was
mentioned that a pilot study had already shown that this sub-
stance is able to increase feelings of disgust. The findings of
this study were illustrated with a poster attached to the wall of
the lab. The subjects were asked to rate the distilled water
according to experienced valence (1 = ‘very pleasant‘; 9 = ‘very
unpleasant‘) and odor intensity (1 = ‘does not smell at all‘, 9 =
‘smells very intensely‘). None-responding had been defined by
an intensity rating of ‘1’ (n = 9).
Disgust proneness The participants answered the
Questionnaire for the Assessment of Disgust Proneness
(QADP; Schienle et al. 2002a). This personality trait refers
to the general tendency of a person to experience disgust
across different situations. The self-report measure consists
of 37 items that have to be judged on 5-point scales
(0 = ‘not disgusting’, 4 = ‘very disgusting’), e.g. ‘you smell
vomit’. The Cronbach’s alpha of the total scale is .90. The
mean QADP score was 2.09 (SE = 0.10), which did not differ
from the score of the construction sample (p = .40).
Pictures and design A total of 90 affective images from the
categories Disgust (e.g., rotten food, poor hygiene), Fear (e.g.,
acts of violence, dangerous predators), and Neutral (pixelated
disgust and fear images) were administered. Each category
consisted of 30 different pictures, which had been divided into
two parallel sets of 15 pictures each. The images were selected
from the International Affective Picture System (IAPS; Lang
et al. 2008) and from a validated set of the authors (Schienle
et al. 2002b).1 The images were presented for 4 s each in
pseudorandomized order to avoid that more than two pictures
of the same category were presented in succession. The inter-
stimulus intervals (presentation of a fixation cross) varied be-
tween 3.5 and 8 s. Each image was shown twice within each
condition (= 30 events per picture category).
The experiment consisted of a nocebo condition and a con-
trol condition (without nocebo) during which the participants
passively viewed affective images (30 Disgust, 30 Fear, 30
Neutral). The two conditions were separated by a short break
(approximately 3 min), during which Olfatape was either at-
tached or removed. The sequence of the two conditions was
balanced across the participants. Further, the sequence of the
two parallel picture set was counterbalanced across the
conditions.
At the end of the nocebo and the control condition the
subjects were presented with three slides depicting an over-
view of the previously viewed pictures representing an affec-
tive category (Disgust, Fear, Neutral). They were asked to rate
experienced arousal, disgust, and fear on 9-point-Likert scales
(9 = very arousing, disgusting, fear-eliciting). This rating pro-
cedure was the same as in the previous ‘disgust placebo’ study
(Schienle et al. 2014a).
fMRI recording
The fMRI session was conducted with a 3 T scanner (Skyra,
Siemens, Erlangen, Germany). Functional runs were acquired
using an echo-planar imaging protocol (number of slices: 35,
descending, flip angle =90°, slice thickness: 3 mm; matrix:
64 × 64 mm; TE = 30 ms; TR = 2290 ms; FoV: 192 mm;
in-plane resolution =3 × 3 × 3 mm). All analyses were con-
ducted using SPM12 (Wellcome Department of Cognitive
Neurology, London). Three volumes from the beginning of
the time series were discarded to account for saturation effects.
First, acquisition timing was accounted in a slice timing
step followed by motion-correction in the realignment and
unwarping step. Afterwards, individuals T1 images were
coregistered to their functional data and were segmented into
greymatter (GM), white matter (WM) and cerebrospinal fluid.
To increase inter-subject alignment individual images of GM
and WM were registered in a ‘Fast Diffeomorphic
Registration Algorithm’ (DARTEL) to the IXI550 template
implemented in the VBM 8 toolbox. Resulting individual
DARTEL flow fields were used to normalize slice-timed,
realigned and unwarped functional images to MNI-space
(3 mm isotropic voxels). Finally, for smoothing a Gaussian
kernel of 6 mm was applied. Vectors for each event of interest
(picture onset) were compiled and entered into the design
matrix to model event-related responses by the canonical he-
modynamic response function in the first level stage. Data
were high pass filtered (128 s). As realignment and unwarping
already model the B0*motion interaction, motion parameters
were not included in the first level analysis as regressors.
Temporal sphericity was controlled by an AR(1) process with
consecutive prewhitening of the data.
fMRI analyses
For the fMRI data, planned t-contrasts (e.g., Disgust >
Neutral; Disgust > Fear) were computed to compare the
1 The numbers of the IAPS pictures (Lang et al. 1999) were: 9300, 9320, 9570
for disgust and 1300, 3500, 3530, 6212, 6230, 6312, 6350, 6370, 6510, 6540,
6940, 9910, 9921, 0014, 1525, 2690, 6260, 6300, 6313, 6315, 6530, 6571,
9250, 9912, 9920 for fear images. The remaining pictures were taken from a
validated picture set from Schienle et al. (2002b).
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two conditions (Nocebo, Control). Exploratory whole-brain
voxel intensity tests were conducted as well as region of in-
terest (ROI) analyses for the amygdala (number of
voxels: left (L) 64, right (R) 75), the insula (L: 569, R:
527), the hippocampus (L: 283, R: 262), and the OFC
(L: 1522, R: 1552). These regions were selected based
on previous findings on disgust and nocebo effects (e.g.,
Schienle et al. 2002a, b, Wager and Atlas 2015). Additional
ROIs involved in odor perception/ imagery were chosen
(piriform cortex (L: 415, R: 467), entorhinal cortex (L: 81,
R: 94)).
Further, multiple regression analyses were conducted to cor-
relate QADP scores with ROI activation. The used ROI masks
were taken from the AAL atlas (Tzourio-Mazoyer et al. 2002)
and were created with the WFU PickAtlas (WFU Pickatlas
v2.4; Wake Forest University School of Medicine). The AAL
atlas was created by the anatomical parcellation of a single-
subject T1-weighted volume with manually drawn regions of
interest. For all analyses the height threshold was set at
p < 0.001 uncorrected for at least five contiguous voxels.
Results were small volume-corrected and considered signifi-
cant if p < .05 (corrected for family-wise error (FWE)).
Moreover, psychophysiological interaction (PPI) analyses
(Friston et al. 1997) were conducted to investigate functional
connectivity in the two conditions (Nocebo, Control). PPI
assesses the extent to which an experimental factor modulates
the connectivity of one brain region with others, in terms of
condition-specific covariation in residuals. Given specific
seed regions, PPI identifies voxel activation that covaries dif-
ferentially with the seed region as a function of an experimen-
tal factor. For each participant, a PPI analysis was performed
by setting up a design matrix containing three columns of
variables: the first regressor, the physiological variable, repre-
sents the time series of activity taken from the seed region by
taking the first eigenvariate of the corresponding mask. The
second regressor, the psychological variable, represents the
condition type (e.g. the contrast Nocebo_Disgust >
Nocebo_Neutral). The PPI variable (PPI term) represents the
third regressor, which was computed as the element by ele-
ment product of the deconvolved extracted time series of the
selected seed region and a vector coding for the effect of task.
Subject-specific contrast images were then entered into a
paired t-test analysis in order to explore connectivity
(Disgust > Neutral) for the contrasts Nocebo > Control and
Control > Nocebo.
The left OFC was defined as seed region, because here
significant activation for the contrast Nocebo > Control:
Disgust > Neutral occurred (nocebo activation). For the PPI
analyses the height threshold was set at p < 0.05 uncorrected
for at least five contiguous voxels. Results were small volume
corrected and considered significant if p < .05 (corrected for




Nocebo ratings The nocebo responders gave the following
ratings for the distilled water: M(intensity) = 4.07 (SE = .25;
range: 3–7), and M(valence) = 5.79 (SE = .21).
Picture ratings The ratings were analyzed with repeated mea-
sures ANOVAs (SPSS; version 22) with the within-subject
factors Picture Category (Disgust, Fear, Neutral) and
Condition (Nocebo, Control). We report η2p (partial eta2) as
effect size measure as well as Greenhouse-Geisser epsilon (ɛ).
Significant effects were followed up with post-hoc t-tests with
Bonferroni correction (cut off: alpha/3 = .017).
The conducted ANOVA for the disgust ratings of the im-
ages revealed significant effects for Picture Category
(F(2,27) = 275.61, p < .001, ɛ = .911, η2p = .953) and the
interaction Picture Category x Condition (F(2,27) = 4.30,
p = .044, ɛ = .800, η2p = .242). The main effect for
Condition was marginally significant F(1,28) = 3.31,
p = .08, η2p = .106). The conducted post-hoc t-tests showed
that the nocebo administration increased experienced disgust
for the Disgust images (p = .001), but not for Fear and Neutral
images (p’s > .53).
Fig. 1 Nocebo administration
Brain Imaging and Behavior
For the fear ratings, only the effect for Picture Category
reached statistical significance (F(2,27) = 59.07, p < .001,
ɛ = .963, η2p = .814). Fear images received higher fear ratings
than Disgust and Neutral pictures (all p’s < .01).
The conducted ANOVA for the arousal ratings revealed
significant main effects for Condition (F(1,28) = 7.93,
p = .009, η2p = .221) and Picture Category (F(2,27) = 39.51,
p <. 001, ɛ = .984, η2p = .721). The conducted post hoc t-tests
showed that the nocebo administration increased arousal rat-
ings (p = .009) and that Disgust pictures and Fear pictures were
perceived as more arousing than Neutral pictures (both
p’s < .001). Arousal ratings for Disgust and Fear pictures did
not differ from each other (p = .24). The ratings are
displayed in Table 1. The introduction of an additional
factor Sequence (nocebo-control vs. control-nocebo) to
the analyses of variance produced no significant main or
interaction effects (all p’s > .15).
Correlation analysesDisgust proneness (QADP) was neither
correlated with nocebo-related changes in disgust experience
(difference: Nocebo – Control) for Disgust images nor with
intensity and valence ratings for the nocebo (all p’s > .16).
Nocebo-related changes in disgust experience were not corre-
lated with nocebo ratings (both p’s > .62).
Brain imaging
The Disgust pictures (contrast: Disgust > Neutral) elicited
activation in the selected regions of interest (insula, amygdala,
OFC, piriform cortex, hippocampus) during the control con-
dition as well as during nocebo administration (Table 2).
These ROIs were also recruited during fear processing (con-
trast: Fear > Neutral).
Relative to the control condition, the nocebo was associat-











Disgust 6.72 (.28) 7.38 (.25)
Fear 2.69 (.31) 3.24 (.35)
Arousal 4.93 (.33) 5.48 (.41)
Fear pictures
Disgust 2.55 (.27) 2.76 (.27)
Fear 5.62 (.36) 6.17 (.39)
Arousal 4.52 (.34) 5.07 (.33)
Neutral pictures
Disgust 1.52 (.26) 1.48 (.20)
Fear 1.17 (.09) 1.38 (.22)
Arousal 2.00 (.26) 2.52 (.37)
Table 2 Results of the planned t-contrasts for the regions of interests
Region H X Y Z t P(FWE) Cluster
size
Control: Disgust > Neutral
Insula R 27 15 -21 6.95 <.001 164
L -33 24 0 7.88 <.001 192
Amygdala R 24 -6 -15 10.62 <.001 62
L -24 -9 -12 11.36 <.001 45
Hippocampus R 24 -6 -18 9.70 <.001 58
L -21 -9 -12 11.39 <.001 71
Orbitofrontal
cortex
R 30 33 -12 10.41 <.001 140
L -30 33 -9 8.40 <.001 151
Piriform cortex R 36 -36 -15 11.65 <.001 70
L -24 -6 -18 10.67 <.001 47
Nocebo: Disgust > Neutral
Insula R 33 27 0 8.05 <.001 54
L -33 27 3 7.19 <.001 130
Amygdala R 24 -3 -18 9.72 <.001 62
L -21 -3 -18 7.94 <.001 40
Hippocampus R 24 -6 -18 8.09 <.001 28
L -18 -6 -12 6.74 <.001 44
Orbitofrontal
cortex
R 27 33 -15 8.81 <.001 103
L -33 33 -15 9.20 <.001 125
Piriform cortex R 24 -3 -18 9.72 <.001 60
L -21 -3 -18 7.94 <.001 40
Control: Fear > Neutral
Insula R 27 18 -18 7.23 <.001 73
L -33 24 0 6.46 <.001 80
Amygdala R 21 -6 -12 11.15 <.001 66
L -30 -3 -18 8.36 <.001 42
Hippocampus R 18 -6 -12 9.46 <.001 118
L -21 -12 -12 8.18 <.001 97
Orbitofrontal
cortex
R 33 33 -15 10.50 <.001 169
L -36 27 -15 7.18 <.001 147
Piriform cortex R 36 -36 -15 11.52 <.001 100
L -27 -42 -9 8.89 <.001 50
Nocebo: Fear > Neutral
Insula R 33 24 0 5.48 .002 29
L -36 24 3 4.86 .007 19
Amygdala R 30 -3 -21 7.65 <.001 50
L -30 -3 -21 6.60 <.001 23
Hippocampus R 30 -6 -21 6.66 <.001 59
Orbitofrontal
cortex
R 36 33 -15 7.23 <.001 109
L -3 39 -21 6.02 <.001 57
Piriform cortex R 36 -39 -12 12.20 <.001 94
L -24 -42 -9 9.13 <.001 40
Nocebo > Control: Disgust > Neutral
Orbitofrontal
cortex
L -18 48 -15 4.78 .018 15
H hemisphere, x,y,z MNI coordinates, p(FWE) p-value (corrected for
family-wise error), cluster size number of voxels in associated cluster
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Control: Disgust > Neutral; Fig. 2). The reversed contrast, as
well as Fear > Neutral produced no significant effects. A sim-
ilar result characterized the contrast Disgust > Fear with stron-
ger orbitofrontal activation in the nocebo condition (x,y,z, left:
−42,30,24, t = 4.36, p(FWE) = 0.025, cluster size =259
voxels). There were no significant whole brain effects.
The regression analysis revealed a positive correlation be-
tween QADP scores and orbitofrontal activity in the left (x,y,z:
−9,42,-12, t = 4.46, p(FWE) = 0.043, cluster size =149 voxels)
and right hemisphere (x,y,z: 6,42,-18, t = 5.02,
p(FWE) = 0.009, cluster size =123 voxels) for the contrast
Nocebo > Control: Disgust > Neutral.
For the PPI analysis the left OFC was chosen as the seed,
because this area had been activated by the nocebo. The OFC
showed enhanced coupling with the right piriform cortex (x,y,z:
30,-39,-9, t = 4.51, p(FWE) = 0.011, cluster size =117), the left
insula (x,y,z: −27,12,-15, t = 3.96, p(FWE) = 0.032, cluster size
=20), the right OFC (x,y,z: 42,36,-15, t = 4.75, p(FWE) = 0.018,
Fig. 2 Increased left orbitofrontal cortex (OFC) activation during nocebo administration and increased connectivity with regions of interest (right OFC,
hippocampus, piriform cortex, left insula)
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cluster size =318) and the right hippocampus (x,y,z: 36,-18,-24,
t = 3.83, p(FWE) = 0.015, cluster size =54) in the nocebo con-
dition relative to the control condition (see Fig. 2).
Discussion
This fMRI study investigated the emotion specificity of nocebo
effects. Themajority of invited participants (76.3%) reported an
odor perception in accordance with the cover story regarding a
‘smell study’. These nocebo responders perceived ‘Olfatape’ as
a slightly unpleasant stimulus of mild to moderate intensity. In
addition, the nocebo altered the processing of affective images.
This was shown in a slight, but statistically significant increase
in experienced disgust. The nocebo-related disgust amplifica-
tion was restricted to the disgust condition and was not present
during the viewing of fear-inducing or neutral images. In other
words, the nocebo elicited an emotion-specific effect.
It should be noted that compared with previously observed
effects relating to a ‘disgust placebo’ (Schienle et al. 2014a,
b), where the experienced disgust intensity was almost halved,
the nocebo-related increase seen here was relatively small.
This however corresponds with the suggestion of an aversive
odorant of very low intensity (close to the sensory threshold).
A different nocebo type had been used in a pilot study: a
nocebo pill labeled as a nausea-inducing medication. This
treatment however not only increased disgust but also feelings
of anxiety and concerns about possible side effects of this
drug. Thus, it was not possible to develop an emotion-
specific nocebo with higher intensity based on this method.
The brain imaging data were in line with the self-report
data. In the control condition, the disgust images elicited acti-
vation in the predefined ROIs, such as the insula, the amyg-
dala, and the OFC, underlining the point that we were able to
provoke the target emotions (e.g., Phan et al. 2002).
The nocebo augmented activation of the left OFC. Similar
results have been reported before by Freeman et al. (2015). In
this study, the application of an inert cream labeled as Capsaicin
(an irritant, which produces a burning skin sensation) evoked
increased expectancies regarding pain and significant blood
flow changes in the OFC. Furthermore, prior studies on place-
bo analgesia have demonstrated that positive expectations and
evaluations were mediated by this frontal area (e.g., Petrovic
et al. 2002; Wager and Atlas 2015). Petrovic et al. (2005) have
suggested that the lateral OFC participates in a generalized
expectancy modulatory network. In line with this are the find-
ings from Sarinopoulos et al. (2006) who presented their sub-
jects with a highly aversive bitter taste. A placebo instruction,
that the stimulus would only bemoderately bitter, inducedOFC
activation predicting subsequent attenuation of bilateral insula
responses. Thus, the OFC does appear to be a shared brain
region of the placebo and nocebo network.
Findings from the connectivity analysis of the present ex-
periment point to a possible nocebo mechanism. During
nocebo administration, the left OFC showed enhanced cou-
pling with the right piriform cortex, the left insula, the right
OFC and the right hippocampus. Previous research has found
the insula and the hippocampus to be most consistently in-
volved in nocebo responses, e.g. during nocebo hyperalgesia
(Wager and Atlas 2015; Schmid et al. 2015). Wager and Atlas
(2015) conceptualized the placebo/nocebo response as a
‘meaning response’, which is based on expectancies (OFC),
interoceptive assessments of one’s own body state (insula),
and autobiographical memories (hippocampus). In the present
investigation exactly these regions were identified, together
with the piriform cortex (PC), which possibly added a specific
sensory ingredient (odor illusion) to this meaning response.
The PC is involved in odor identification and the assignment
of odor valence. It plays an active role, from the sensory to
more cognitive aspects of human olfactory perception (for a
review see Bensafi 2012). Bensafi et al. (2007) demonstrated
that the PC is not only involved in the smelling of an actual
odor, but is also recruited during odor imagery. Our nocebo
instruction very likely triggered such imagery processes.
The present study has important clinical implications. The
neuropsychological processes that mediate affective nocebo
effects may be relevant for a wide array of therapeutic ap-
proaches, including the treatment of somatic conditions as
well as psychotherapy (Benedetti et al. 2007). It is generally
accepted that one basic prerequisite for meaningful change in
behavior therapy is the elicitation of realistic expectations for
treatment (Leutgeb et al. 2009). For example, in the context of
exposure therapy for specific phobias (e.g., spiders, blood),
patients are told that confrontation with the disorder-relevant
stimulus will have adverse effects including the occurrence of
intense negative feelings (e.g., fear, disgust). According to our
data, this approach might amplify the negative evaluation of
the phobic stimulus and may therefore become a roadblock to
change. The correlation analysis indicated that disgust-prone
women (with high QADP scores) showed enhanced nocebo-
related OFC activation. Considering that patients with a blood
or spider phobia are also characterized by an elevated prone-
ness to disgust, this finding underlines the clinical relevance of
affective nocebo effects (Leutgeb et al. 2009).
The following limitations of our investigation need to
be mentioned. Only women were investigated, since they
are characterized by greater disgust responsivity (Schienle
et al. 2002a, b). This reduced inter-gender variance, but
as a consequence the findings cannot be generalized to
men. Furthermore, the number of non-responders (n = 9)
was not sufficient to compare their brain responses with
those of the responders. Future studies should include
such a group to be able to further deepen our knowledge
about affective nocebo responding. Also, the inclusion of
a placebo condition would allow to identify specific as
well as shared neuronal components of placebo/nocebo
responses.
Brain Imaging and Behavior
In conclusion, to the best of our knowledge, this is the first
fMRI study on affective (disgust-related) nocebo effects. The
study demonstrated that a nocebo was able to elicit a new
symptom (‘aversive odor’) and to intensify visually induced
disgust. Moreover, OFC activation and connectivity were spe-
cifically influenced by the nocebo.
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